Venus Medtech (启明医疗) & Peijia Medical (沛嘉医疗) Placement - Take Your Pick

MicroPort CardioFlow: PHIP Updates and More on TMV

MicroPort CardioFlow: What You Have to Assume

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

Microport Cardioflow Medtech / Equity Capital Markets

<p>MicroPort Cardioflow Medtech Corporation, a 67%-owned subsidiary of MicroPort Scientific, is a leading medical device company in China. The company’s primary product is VitaFlow, a transcatheter aortic valve implantation (“TAVI” or “TAVR”) device, used to treat Aortic stenosis. TAVR is an emerging medical procedure in China with a handful of competitors at the moment.  The company has filed an Application Proof to list on the HKEX.</p><p>This Insight will discuss the company’s products, market opportunity, IP, etc. We will provide more details closer to the offering in a future Insight.</p>

MicroPort Cardioflow Medtech Corporation, a 67%-owned subsidiary of MicroPort Scientific, is a leading medical device company in China. The company’s primary product is VitaFlow, a transcatheter aortic valve implantation (“TAVI” or “TAVR”) device, used to treat Aortic stenosis. TAVR is an emerging medical procedure in China with a handful of competitors at the moment.  The company has filed an Application Proof to list on the HKEX.This Insight will discuss the company’s products, market opportunity, IP, etc. We will provide more details closer to the offering in a future Insight.

Microport Cardioflow Medtech

Microport Cardioflow: Winning in TAVR